In vivo editing has a late-stage signal.
Phase 3 HAE data make one-time systemic editing a current diligence problem rather than a distant platform promise.
Gene TherapyGenome editingRNA editingEpigenome control
Gene Therapy
As of June 2026, gene therapy is separating by permanence class. Ex vivo CRISPR is approved, systemic in vivo CRISPR has late-stage human data, RNA editing is moving toward regulatory feedback, and epigenome editing is testing whether durable regulation can be tuned rather than permanent.
Domain research lens
This page tracks delivery, edit durability, reversibility, off-target risk, tissue specificity, rescue logic, and whether the modality fits the disease mechanism.
June 2026 field state
A field moving from edit feasibility to permanence discipline.
The strongest programs ask whether the right tissue, dose, edit type, reversibility, and long-term follow-up burden match the disease.
Therapeutic platforms that edit, replace, silence, repair, regulate, or compensate for DNA, RNA, chromatin, and variant-to-function disease mechanisms.
The domain thesis: the strategic question is not DNA versus RNA versus epigenome. It is whether the required duration of effect matches the tolerable uncertainty.
RNA editing can occupy a reversible permanence class.
Clinical AATD data are testing correction without permanent DNA alteration.
Safety scales with permanence.
Off-target, immune, liver, biodistribution, durability, retreatment, and reversibility questions become more consequential as edits become harder to reverse.
Recent research signals
The 2025-2026 update is a decision-gate wave.
Each signal below starts from the field: what changed, why it matters, and which research or buyer decision becomes more testable.
A systemic in vivo CRISPR program reported Phase 3 HAE data.
Intellia reported additional Phase 3 HAELO data for lonvoguran ziclumeran, a one-time KLKB1 gene-editing therapy for hereditary angioedema.
Why it matters
Late-stage human data make durability, safety monitoring, and chronic-therapy substitution immediate questions.
Decision implication
Changes whether in vivo editing is evaluated as a platform story or disease-specific permanence tradeoff.
FDA safety expectations became more explicit.
FDA issued draft guidance on safety assessment of genome editing in human gene therapy products using next-generation sequencing.
Why it matters
Standardized off-target and safety expectations influence which platform claims can move toward IND and BLA packages.
Decision implication
Changes assay investment, IND-readiness, and long-term follow-up planning.
Clinical RNA editing is testing reversible genetic correction.
Wave reported RestorAATion-2 data for WVE-006 in alpha-1 antitrypsin deficiency and expected FDA feedback on a potential accelerated path in mid-2026.
Why it matters
RNA editing offers a repeatable and potentially reversible class, but it depends on dosing, tissue delivery, phenotype threshold, and durability.
Decision implication
Changes whether a buyer should prefer RNA correction over permanent DNA editing.
FDA opened a draft path for leveraging prior knowledge in genome-editing gene therapy.
FDA issued draft guidance on leveraging prior knowledge in human gene therapy products incorporating genome editing.
Why it matters
Rare and modular programs may be able to reduce redundant evidence if the mechanism, platform, and prior knowledge are credibly bridged.
Decision implication
Changes platform reuse, target expansion, and rare-disease development strategy.
What leading groups are working on
The current edge is a set of validation programs, not a single breakthrough story.
These representative programs and research fronts frame the active field before the page maps Zemi Dossiers into it.
In vivo CRISPR
One-time systemic editing reaches Phase 3 evidence
Lonvo-z/NTLA-2002 makes HAE a live test of whether permanent KLKB1 editing can replace chronic prophylaxis while maintaining safety and attack-free durability.
Safety standardsNGS-based off-target assessment becomes a regulatory design layer
FDA's 2026 draft guidance pushes sponsors to define assay sensitivity, input material, sequencing depth, bystander edits, and chromosome-integrity risks early.
RNA editingRepeatable correction without permanent DNA change
WVE-006 in AATD is testing whether an RNA edit can produce a protective phenotype across lung and liver disease with practical monthly or biweekly dosing.
Platform reusePrior-knowledge bridging for modular editing programs
FDA's June 2026 draft guidance makes platform similarity, target differences, nonclinical relevance, and clinical bridge evidence part of the development strategy.
Regulation without cuttingEpigenome editing and expression control
Programmable repression, activation, and epigenetic tuning are being evaluated where permanent sequence change is too risky or the disease biology requires graded control.
Decision gates
What must be true before a buyer should build, fund, partner, monitor, avoid, or run the next study.
These are field-level gates first. The dossier library appears later as the set of existing Zemi products that can help investigate them.
Permanence fit
Does the disease justify permanent, transient, repeatable, or tunable intervention?
Delivery bottleneck
Can the modality reach the right tissue and cell type at a tolerable dose?
Off-target burden
Are assay sensitivity, biodistribution, and follow-up matched to risk?
Rescue evidence
Does the variant or mechanism respond in a decision-changing model?
Retreatment logic
Can the patient be retreated, reversed, rescued, or safely monitored?
Regulatory package
Is the trial design credible for small populations and long-duration uncertainty?
Zemi Dossiers in this domain
The dossiers sit where new research creates hard buyer decisions.
Each dossier card uses stats from the actual research report manifest and Evidence & Decision Workbook, including pages, workbook sheets, evidence/source rows, claim rows, power rows, and decision instruments where present.
Primary Zemi Dossier
In Vivo Gene Editing
Turns in-vivo editing from a modality story into a coupled-system failure-mode map.
Why it belongs here
Which in-vivo editing programs are limited by edit chemistry, delivery, immune response, durability, or CMC before pivotal spend?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
RNA Editing & the Permanence Spectrum
Positions RNA editing on a permanence spectrum so buyers do not confuse reversibility with durability or safety by default.
Why it belongs here
Which RNA-editing programs should rent correction, extend correction, or avoid RNA-level strategy based on permanence needs?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Primary Zemi Dossier
Epigenome Editing & Tunable Permanence
Classifies whether mitotic dilution, active erasure, or reactivation pressure will dominate before buyers commit to delivery, indication, or permanence strategy.
Why it belongs here
Which epigenome-editing programs have a defensible durability strategy, and what decay force would erase the imposed mark before benefit is proven?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Cell Therapy for Autoimmune Disease
Distinguishes remission achieved from durability solved by mapping persistence, sanctuary, and immune reconstitution risks.
Why it belongs here
Which autoimmune cell-therapy programs have a credible durability path, and what would reveal relapse risk before scale-up?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Immune Aging Supply Chain
Routes immune-aging programs to the binding supply-chain node before treating broad immune decline as one therapeutic target.
Why it belongs here
Which immune-aging interventions target the binding node, and when would restoration create more risk than resilience?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Genetic Cardiomyopathy Precision Therapies
Uses molecular mechanism rather than gene label to route programs toward addition, knockdown, editing, or avoidance logic.
Why it belongs here
Which genetic cardiomyopathy programs match mechanism, modality, delivery, safety window, and evidentiary standard well enough to advance?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
AI Multi-Omics Variant-to-Rescue
Routes variant interpretation toward rescue experiments instead of stopping at association, prediction, or annotation confidence.
Why it belongs here
Which variant-to-function programs have enough evidence to justify rescue experiments, and what readout would falsify the rescue thesis?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
AI Biology Drug Discovery
Separates static generation wins from the harder validation problem: whether AI can predict dynamic biological response under prospective tests.
Why it belongs here
Which AI-biology programs deserve validation spend now, and what experiment would show whether the model changes a real discovery decision?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Partial Epigenetic Reprogramming
Maps the rejuvenation-transformation margin so buyers can distinguish clock movement from functional, controlled, and safe benefit.
Why it belongs here
Which partial-reprogramming programs have enough control, reversibility, and safety-margin evidence to justify next validation?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Ovarian Aging Multi-Clock
Separates endocrine, follicular, mitochondrial, stromal, and functional clocks before buyers infer benefit from measurement movement.
Why it belongs here
Which ovarian-aging readouts represent functional benefit, and which only move a clock without changing the decision?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Adjacent / cross-domain
Mitochondrial Medicine Permanence Ladder
Maps mitochondrial interventions onto a permanence ladder so buyers do not overbuild or underbuild the required correction.
Why it belongs here
Which mitochondrial programs need transient support, durable shift, editing, replacement, or avoidance based on heteroplasmy and tissue constraints?
Pairs the research report with workbook evidence rows, claim discipline, decision instruments, power calculations, and next-study surfaces.
Watchlist
Signals that would change the map in 2026-2028.
These are the developments most likely to change the field map, evidence posture, or next-study priorities.
In vivo editing
Lonvo-z BLA path and long-term safety
Approval would make systemic in vivo CRISPR a current treatment-category problem rather than a platform forecast.
RNA editingWVE-006 FDA feedback and phenotype durability
The field needs to know whether monthly RNA editing can sustain a clinically meaningful protective phenotype.
Regulatory scienceGenome-editing safety guidance finalization
Final NGS expectations would change assay buildout, IND readiness, and long-term follow-up planning.
Epigenome editingDurability without transformation risk
Expression-control programs need evidence that tunability does not hide long-term cell-state or oncogenic liabilities.
Field-note discipline
Current-state pages need a source-aware update layer.
The public page stays readable, but the underlying domain model tracks source-linked developments that change evidence posture, buyer decisions, or next-study priorities.
June 2026 / In vivo CRISPR
The modality question is now permanence fit.
A one-time therapy can be attractive only when disease severity, durability, safety monitoring, and retreatment limits match the mechanism.
May 2026 / RNA editing RNA editing occupies a distinct permanence class.The diligence question is not whether it is safer by default, but whether repeat dosing can sustain enough correction with acceptable burden.
2026 / FDA guidance Regulatory expectations are becoming part of platform design.Safety assays and prior-knowledge bridging now shape which editing programs are economical to expand.
From domain signal to Zemi Dossier
Request access to inspect the full research report, Evidence & Decision Workbook, power calculations, and release-audit surfaces behind each decision package.